KEDM.com on X
Tiny, but perhaps interesting. Neuphoria $NEUP will be acquired by Scancell in an all share merger, resulting in a Nasdaq-listed Scancell (SCLT) alongside Scancell’s AIM listing. The current ratio implies $4.55 per NEUP share (~16% gross spread), plus a few CVRs tied to several milestones. partnered asset milestones. The deal is paired with up to $89m of new financing, plus $10m of Neuphoria cash, to fund Scancell’s Phase 3 iSCIB1+ lead melanoma trial through key readouts into 2029.
